3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Lung Neoplasms
24
Squamous Cell Carcinoma of Head and Neck
23
Oropharyngeal Neoplasms
13
Urinary Bladder Neoplasms
12
Nasopharyngeal Carcinoma
12
Carcinoma
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
9
Biliary Tract Neoplasms
8
Head and Neck Neoplasms
7
Uterine Cervical Neoplasms
6
Small Cell Lung Carcinoma
6
Pancreatic Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Endometrial Neoplasms
6
Colorectal Neoplasms
6
Cholangiocarcinoma
6
Neoplasms
5
Neoplasm Metastasis
5
Mouth Neoplasms
5
Laryngeal Neoplasms
5
Stomach Neoplasms
4
Hypopharyngeal Neoplasms
4
Esophageal Neoplasms
4
Ovarian Neoplasms
3
Mesothelioma, Malignant
3
Lymphoid Interstitial Pneumonia
3
Lung Diseases
3
Carcinoma, Transitional Cell
3
Carcinoma, Squamous Cell
3
Interventions
pembrolizumab
2
enfortumab vedotin
2
Gemcitabine
2
testosterone 17 beta-cypionate
1
temsirolimus
1
Valproic Acid
1
Testosterone Propionate
1
Standard of Care
1
Sirolimus
1
Radiation Dose Hypofractionation
1
Practice Guidelines as Topic
1
Mitomycin
1
Methyltestosterone
1
Immunoglobulin G
1
Fluorouracil
1
Disulfides
1
Cisplatin
1
Cetuximab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Cisplatin
×
30 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled